Abstract A137: Initial testing (Stage 1) of EPZ-6438 (tazemetostat), a novel EZH2 inhibitor, by the pediatric preclinical testing program (PPTP)
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):